{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T13:38:56Z","timestamp":1789133936565,"version":"build-2803163510"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","award":["CO-US-380-5483"],"award-info":[{"award-number":["CO-US-380-5483"]}],"id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shanghai Public Health Clinical Center","award":["RCJJ2025-10"],"award-info":[{"award-number":["RCJJ2025-10"]}]},{"name":"Shanghai Public Health Clinical Center","award":["Grant Number KY-GW-2025-12"],"award-info":[{"award-number":["Grant Number KY-GW-2025-12"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s40121-025-01262-8","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T03:18:00Z","timestamp":1763695080000},"page":"165-181","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Bone Mineral Density Changes in People with HIV Who had Immediate Switch Versus Deferred Switch from Tenofovir Disoproxil Fumarate-Based Regimens to Bictegravir\/Emtricitabine\/Tenofovir Alafenamide: A Multicenter, Open-Label, Randomized Clinical Trial"],"prefix":"10.1007","volume":"15","clinical-trial-number":[{"clinical-trial-number":"nct05122754","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Yueming","family":"Shao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinping","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhua","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xicheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangrong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zongxing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renfang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinzhong","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiyan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luling","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihang","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tangkai","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuibao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingna","family":"Xun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3850-4875","authenticated-orcid":false,"given":"Jun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,21]]},"reference":[{"issue":"8","key":"1262_CR1","doi-asserted-by":"publisher","first-page":"2938","DOI":"10.1210\/jc.2006-0127","volume":"91","author":"SE Dolan","year":"2006","unstructured":"Dolan SE, Kanter JR, Grinspoon S. Longitudinal analysis of bone density in human immunodeficiency virus-infected women. J Clin Endocrinol Metab. 2006;91(8):2938\u201345.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1262_CR2","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1086\/367569","volume":"36","author":"K Mondy","year":"2003","unstructured":"Mondy K, Yarasheski K, Powderly WG, et al. Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. Clin Infect Dis. 2003;36(4):482\u201390.","journal-title":"Clin Infect Dis"},{"issue":"7","key":"1262_CR3","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1086\/501015","volume":"42","author":"JH Arnsten","year":"2006","unstructured":"Arnsten JH, Freeman R, Howard AA, Floris-Moore M, Santoro N, Schoenbaum EE. HIV infection and bone mineral density in middle-aged women. Clin Infect Dis. 2006;42(7):1014\u201320.","journal-title":"Clin Infect Dis"},{"issue":"11","key":"1262_CR4","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1097\/QAD.0000000000001507","volume":"31","author":"S Bregigeon","year":"2017","unstructured":"Bregigeon S, Galinier A, Zaegel-Faucher O, et al. Frailty in HIV infected people. AIDS. 2017;31(11):1573\u20137.","journal-title":"AIDS"},{"issue":"1","key":"1262_CR5","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1186\/s12879-021-06263-9","volume":"21","author":"P Atencio","year":"2021","unstructured":"Atencio P, Cabello A, Conesa-Buend\u00eda FM, et al. Increased risk factors associated with lower BMD in antiretroviral-therapy-na\u00efve HIV-infected adult male. BMC Infect Dis. 2021;21(1):542.","journal-title":"BMC Infect Dis"},{"issue":"2","key":"1262_CR6","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.jmii.2012.08.026","volume":"47","author":"MS Tsai","year":"2014","unstructured":"Tsai MS, Hung CC, Liu WC, et al. Reduced bone mineral density among HIV-infected patients in Taiwan: prevalence and associated factors. J Microbiol Immunol Infect. 2014;47(2):109\u201315.","journal-title":"J Microbiol Immunol Infect"},{"issue":"1","key":"1262_CR7","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s11657-021-00903-y","volume":"16","author":"CJ Chang","year":"2021","unstructured":"Chang CJ, Chan YL, Pramukti I, Ko NY, Tai TW. People with HIV infection had lower bone mineral density and increased fracture risk: a meta-analysis. Arch Osteoporos. 2021;16(1):47.","journal-title":"Arch Osteoporos"},{"issue":"3","key":"1262_CR8","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1097\/QAI.0000000000002958","volume":"90","author":"W Meng","year":"2022","unstructured":"Meng W, Chen M, Song Y, Zhang H, Xie R, Zhang F. Prevalence and risk factors of low bone mineral density in hiv\/aids patients: a Chinese cross-sectional study. J Acquir Immune Def Syndr (1999). 2022;90(3):360\u20138.","journal-title":"J Acquir Immune Def Syndr (1999)"},{"issue":"1","key":"1262_CR9","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1007\/s11657-024-01413-3","volume":"19","author":"Y Shao","year":"2024","unstructured":"Shao Y, Sun J, Kong K, et al. Prevalence and associated factors of low bone mineral density in people living with HIV: a cross-sectional study. Arch Osteoporos. 2024;19(1):56.","journal-title":"Arch Osteoporos"},{"issue":"9987","key":"1262_CR10","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1016\/S0140-6736(15)60616-X","volume":"385","author":"PE Sax","year":"2015","unstructured":"Sax PE, Wohl D, Yin MT, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet. 2015;385(9987):2606\u201315.","journal-title":"Lancet"},{"issue":"7","key":"1262_CR11","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1097\/QAD.0b013e32835192ae","volume":"26","author":"R Bedimo","year":"2012","unstructured":"Bedimo R, Maalouf NM, Zhang S, Drechsler H, Tebas P. Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents. AIDS (London, England). 2012;26(7):825\u201331.","journal-title":"AIDS (London, England)"},{"issue":"4","key":"1262_CR12","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1097\/00002030-200303070-00006","volume":"17","author":"M Cozzolino","year":"2003","unstructured":"Cozzolino M, Vidal M, Arcidiacono MV, Tebas P, Yarasheski KE, Dusso AS. HIV-protease inhibitors impair vitamin D bioactivation to 1,25-dihydroxyvitamin D. AIDS (London, England). 2003;17(4):513\u201320.","journal-title":"AIDS (London, England)"},{"issue":"9","key":"1262_CR13","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz333","volume":"6","author":"X Li","year":"2019","unstructured":"Li X, Brown TT, Ho KS, Witt MD, Phair J, Jacobson LP. Recent trends and effectiveness of antiretroviral regimens among men who have sex with men living with HIV in the United States: the Multicenter AIDS Cohort Study (MACS) 2008\u20132017. Open Forum Infect Dis. 2019;6(9):ofz333.","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"1262_CR14","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S1473-3099(15)00348-5","volume":"16","author":"A Mills","year":"2016","unstructured":"Mills A, Arribas JR, Andrade-Villanueva J, et al. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study. Lancet Infect Dis. 2016;16(1):43\u201352.","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"1262_CR15","doi-asserted-by":"publisher","first-page":"e195","DOI":"10.1016\/S2352-3018(17)30031-0","volume":"4","author":"C Orkin","year":"2017","unstructured":"Orkin C, DeJesus E, Ramgopal M, et al. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study. Lancet HIV. 2017;4(5):e195\u2013204.","journal-title":"Lancet HIV"},{"issue":"1","key":"1262_CR16","doi-asserted-by":"publisher","first-page":"e23","DOI":"10.1016\/S2352-3018(17)30179-0","volume":"5","author":"C Orkin","year":"2018","unstructured":"Orkin C, Molina JM, Negredo E, et al. Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial. Lancet HIV. 2018;5(1):e23\u201334.","journal-title":"Lancet HIV"},{"issue":"10","key":"1262_CR17","doi-asserted-by":"publisher","first-page":"e655","DOI":"10.1016\/S2352-3018(19)30195-X","volume":"6","author":"F Maggiolo","year":"2019","unstructured":"Maggiolo F, Rizzardini G, Raffi F, et al. Bone mineral density in virologically suppressed people aged 60 years or older with HIV-1 switching from a regimen containing tenofovir disoproxil fumarate to an elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide single-tablet regimen: a multicentre, open-label, phase 3b, randomised trial. Lancet HIV. 2019;6(10):e655\u201366.","journal-title":"Lancet HIV"},{"issue":"4","key":"1262_CR18","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1097\/QAD.0000000000003811","volume":"38","author":"AEB Moore","year":"2024","unstructured":"Moore AEB, Burns JE, Sally D, et al. Bone turnover change after randomized switch from tenofovir disoproxil to tenofovir alafenamide fumarate in men with HIV. AIDS. 2024;38(4):521\u20139.","journal-title":"AIDS"},{"key":"1262_CR19","unstructured":"Genvoya prescribing information. Available at: https:\/\/www.gilead.com\/-\/media\/files\/pdfs\/medicines\/hiv\/genvoya\/genvoya_pi.pdf. Accessed 9 Apr."},{"issue":"4","key":"1262_CR20","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1097\/QAI.0000000000002589","volume":"86","author":"YS Huang","year":"2021","unstructured":"Huang YS, Cheng CY, Liou BH, et al. Efficacy and safety of Elvitegravir\/Cobicistat\/Emtricitabine\/Tenofovir alafenamide as maintenance treatment in HIV\/HBV-coinfected patients. JAIDS J Acquir Immune Defic Syndr. 2021;86(4):473\u201381.","journal-title":"JAIDS J Acquir Immune Defic Syndr"},{"issue":"Suppl 5","key":"1262_CR21","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/hiv.12440","volume":"17","author":"F Raffi","year":"2016","unstructured":"Raffi F, Esser S, Nunnari G, Perez-Valero I, Waters L. Switching regimens in virologically suppressed HIV-1-infected patients: evidence base and rationale for integrase strand transfer inhibitor (INSTI)-containing regimens. HIV Med. 2016;17(Suppl 5):3\u201316.","journal-title":"HIV Med"},{"key":"1262_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1076739","volume":"14","author":"J Soldado-Folgado","year":"2023","unstructured":"Soldado-Folgado J, Rins-Lozano O, Arrieta-Aldea I, et al. Changes in bone quality after switching from a TDF to a TAF based ART: a pilot randomized study. Front Endocrinol (Lausanne). 2023;14:1076739.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6","key":"1262_CR23","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1111\/hiv.12840","volume":"21","author":"C Schwarze-Zander","year":"2020","unstructured":"Schwarze-Zander C, Piduhn H, Boesecke C, et al. Switching tenofovir disoproxil fumarate to tenofovir alafenamide in a real life setting: what are the implications? HIV Med. 2020;21(6):378\u201385.","journal-title":"HIV Med"},{"issue":"9","key":"1262_CR24","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1097\/QAD.0000000000001067","volume":"30","author":"JL Casado","year":"2016","unstructured":"Casado JL, Santiuste C, Vazquez M, et al. Bone mineral density decline according to renal tubular dysfunction and phosphaturia in tenofovir-exposed HIV-infected patients. AIDS. 2016;30(9):1423\u201331.","journal-title":"AIDS"},{"key":"1262_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/ph17020146","author":"TS Hashwin Singh","year":"2024","unstructured":"Hashwin Singh TS, Jashwin Singh TS, Chin KY. Effects of tenofovir disoproxil fumarate on bone quality beyond bone density-a scoping review of the literature. Pharmaceuticals (Basel). 2024. https:\/\/doi.org\/10.3390\/ph17020146.","journal-title":"Pharmaceuticals (Basel)"},{"key":"1262_CR26","doi-asserted-by":"publisher","DOI":"10.1007\/s00774-022-01365-z","author":"P Vizcarra","year":"2022","unstructured":"Vizcarra P, Rosillo M, Del Rey JM, Moreno A, Vivancos MJ, Casado JL. Unravelling hip-spine bone mineral density discordance in people living with HIV. J Bone Miner Metab. 2022. https:\/\/doi.org\/10.1007\/s00774-022-01365-z.","journal-title":"J Bone Miner Metab"},{"issue":"12","key":"1262_CR27","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1093\/infdis\/jir188","volume":"203","author":"GA McComsey","year":"2011","unstructured":"McComsey GA, Kitch D, Daar ES, et al. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids clinical trials group A5224s, a substudy of ACTG A5202. J Infect Dis. 2011;203(12):1791\u2013801.","journal-title":"J Infect Dis"},{"issue":"2","key":"1262_CR28","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/S2055-6640(20)30248-X","volume":"4","author":"A Hill","year":"2018","unstructured":"Hill A, Hughes SL, Gotham D, Pozniak AL. Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety? J Virus Erad. 2018;4(2):72\u20139.","journal-title":"J Virus Erad"},{"issue":"4","key":"1262_CR29","first-page":"199","volume":"16","author":"F Gutierrez","year":"2014","unstructured":"Gutierrez F, Fulladosa X, Barril G, Domingo P. Renal tubular transporter-mediated interactions of HIV drugs: implications for patient management. AIDS Rev. 2014;16(4):199\u2013212.","journal-title":"AIDS Rev"},{"issue":"3","key":"1262_CR30","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1097\/QAI.0b013e3181eb376b","volume":"55","author":"P German","year":"2010","unstructured":"German P, Warren D, West S, Hui J, Kearney BP. Pharmacokinetics and bioavailability of an integrase and novel pharmacoenhancer-containing single-tablet fixed-dose combination regimen for the treatment of HIV. J Acquir Immune deficiency Syndr (1999). 2010;55(3):323\u20139.","journal-title":"J Acquir Immune deficiency Syndr (1999)"},{"issue":"6","key":"1262_CR31","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1089\/aid.2013.0252","volume":"30","author":"E Kinai","year":"2014","unstructured":"Kinai E, Nishijima T, Mizushima D, et al. Long-term use of protease inhibitors is associated with bone mineral density loss. AIDS Res Hum Retroviruses. 2014;30(6):553\u20139.","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"2","key":"1262_CR32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0017217","volume":"6","author":"JA Womack","year":"2011","unstructured":"Womack JA, Goulet JL, Gibert C, et al. Increased risk of fragility fractures among HIV infected compared to uninfected male veterans. PLoS ONE. 2011;6(2):e17217.","journal-title":"PLoS ONE"},{"issue":"7","key":"1262_CR33","doi-asserted-by":"publisher","first-page":"e347","DOI":"10.1016\/S2352-3018(18)30091-2","volume":"5","author":"ES Daar","year":"2018","unstructured":"Daar ES, DeJesus E, Ruane P, et al. Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial. Lancet HIV. 2018;5(7):e347\u201356.","journal-title":"Lancet HIV"},{"issue":"5","key":"1262_CR34","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/j.jmii.2024.07.003","volume":"57","author":"YT Tseng","year":"2024","unstructured":"Tseng YT, Yang CJ, Kim YS, et al. Twelve-month effectiveness and safety of bictegravir\/emtricitabine\/tenofovir alafenamide in treatment-naive and treatment-experienced people with HIV: findings from the Asia cohort of the BICSTaR study. J Microbiol Immunol Infect. 2024;57(5):760\u201370.","journal-title":"J Microbiol Immunol Infect"},{"key":"1262_CR35","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.jgar.2023.10.012","volume":"36","author":"JY Hsu","year":"2024","unstructured":"Hsu JY, Sun HY, Chen LY, et al. Weight and metabolic changes among virally suppressed people with HIV who switched to co-formulated bictegravir\/emtricitabine\/tenofovir alafenamide. J Glob Antimicrob Resist. 2024;36:426\u201335.","journal-title":"J Glob Antimicrob Resist"},{"issue":"3","key":"1262_CR36","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.idc.2024.04.005","volume":"38","author":"SS Bailin","year":"2024","unstructured":"Bailin SS, Koethe JR. Weight gain and antiretroviral therapy. Infect Dis Clin N Am. 2024;38(3):499\u2013515.","journal-title":"Infect Dis Clin N Am"},{"key":"1262_CR37","unstructured":"Rockstroh J, Molina J-M, Post F, al. e. Poster presented at: Long-term follow-up after a switch to bictegravir, emtricitabine, tenofovir alafenamide (B\/F\/TAF) from a boosted protease inhibitor-based regimen. In: HIV Drug Therapy Glasgow 2020. Virtual, October 5\u20138, 2020."},{"issue":"6","key":"1262_CR38","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1161\/HYPERTENSIONAHA.116.08998","volume":"69","author":"M Kuwabara","year":"2017","unstructured":"Kuwabara M, Niwa K, Hisatome I, et al. Asymptomatic hyperuricemia without comorbidities predicts cardiometabolic diseases: five-year Japanese cohort study. Hypertension. 2017;69(6):1036\u201344.","journal-title":"Hypertension"},{"issue":"4","key":"1262_CR39","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1111\/joim.12520","volume":"280","author":"J Compston","year":"2016","unstructured":"Compston J. HIV infection and bone disease. J Intern Med. 2016;280(4):350\u20138.","journal-title":"J Intern Med"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-025-01262-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-025-01262-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-025-01262-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T11:27:48Z","timestamp":1767871668000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-025-01262-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,21]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["1262"],"URL":"https:\/\/doi.org\/10.1007\/s40121-025-01262-8","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,21]]},"assertion":[{"value":"24 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Yueming Shao, Xinping Yang, Jianhua Yu, Xicheng Wang, Jiangrong Wang, Mei Liu, Zongxing Yang, Jie Han, Renfang Zhang, Li Liu, Yinzhong Shen, Meiyan Sun, Luling Wu, Zhihang Zheng, Yang Tang, Junyang Yang, Zhenyan Wang, Tangkai Qi, Shuibao Xu, Jingna Xun, Jianjun Sun, Wei Song, and Jun Chen declare that they have no competing interests. Jun Chen is an Editorial Board member of Infectious Diseases and Therapy. Jun Chen was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study was approved by the independent ethics committee of Shanghai Public Health Clinical Center (number: 2020-S187-02) and conformed to Good Clinical Practice guidelines and Declaration of Helsinki principles. This study was registered with ClinicalTrials.gov (NCT05122754). All participants provided written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}